Oxygenta Pharmaceutical Limited (BOM:524636)
India · Delayed Price · Currency is INR 58.00
-0.69 (-1.18%)
At close: Feb 12, 2026
Oxygenta Pharmaceutical Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 1,128 | 1,093 | 396.42 | 309.88 | 605.25 | 520.27 |
Other Revenue | - | - | - | -0 | 0 | - |
| 1,128 | 1,093 | 396.42 | 309.87 | 605.25 | 520.27 | |
Revenue Growth (YoY) | 60.31% | 175.71% | 27.93% | -48.80% | 16.33% | 279.03% |
Cost of Revenue | 1,171 | 1,071 | 405.89 | 300.79 | 564.29 | 422.99 |
Gross Profit | -42.35 | 21.86 | -9.47 | 9.08 | 40.96 | 97.28 |
Selling, General & Admin | 82.7 | 70.52 | 61.74 | 60.42 | 7.87 | 42.64 |
Other Operating Expenses | 42 | 46.67 | 25.65 | 19.83 | 18.33 | 16.22 |
Operating Expenses | 138.34 | 125.35 | 113.99 | 100.77 | 42.12 | 70.82 |
Operating Income | -180.68 | -103.5 | -123.46 | -91.69 | -1.15 | 26.47 |
Interest Expense | -35 | -20.17 | -15.81 | -14.75 | -9.15 | -17.75 |
Interest & Investment Income | 0.23 | 0.23 | 0.18 | 0.05 | 0.04 | 0.23 |
Currency Exchange Gain (Loss) | -1.59 | -1.59 | 0.14 | 0.13 | - | - |
Other Non Operating Income (Expenses) | 0.74 | 12.21 | -0.13 | -0.13 | -0.1 | 0.61 |
EBT Excluding Unusual Items | -216.3 | -112.82 | -139.09 | -106.38 | -10.36 | 9.55 |
Gain (Loss) on Sale of Assets | 0.49 | 0.49 | - | - | - | - |
Other Unusual Items | -3.67 | -3.2 | 0.37 | -7.34 | 5.46 | 21.89 |
Pretax Income | -219.48 | -115.53 | -138.72 | -113.73 | -4.89 | 31.44 |
Income Tax Expense | -44.96 | -18.7 | -103.92 | 1.98 | 1.21 | 2.14 |
Net Income | -174.51 | -96.83 | -34.79 | -115.71 | -6.1 | 29.3 |
Net Income to Common | -174.51 | -96.83 | -34.79 | -115.71 | -6.1 | 29.3 |
Shares Outstanding (Basic) | 37 | 36 | 32 | 14 | 13 | 10 |
Shares Outstanding (Diluted) | 37 | 36 | 32 | 14 | 13 | 13 |
Shares Change (YoY) | 4.33% | 12.20% | 125.61% | 11.43% | - | 24.84% |
EPS (Basic) | -4.74 | -2.69 | -1.09 | -8.15 | -0.48 | 2.87 |
EPS (Diluted) | -4.74 | -2.69 | -1.09 | -8.15 | -0.48 | 2.87 |
Free Cash Flow | - | -87.89 | -171.55 | -112.79 | -66.26 | -83.63 |
Free Cash Flow Per Share | - | -2.44 | -5.35 | -7.94 | -5.20 | -6.56 |
Gross Margin | -3.75% | 2.00% | -2.39% | 2.93% | 6.77% | 18.70% |
Operating Margin | -16.01% | -9.47% | -31.14% | -29.59% | -0.19% | 5.09% |
Profit Margin | -15.47% | -8.86% | -8.78% | -37.34% | -1.01% | 5.63% |
Free Cash Flow Margin | - | -8.04% | -43.28% | -36.40% | -10.95% | -16.07% |
EBITDA | -186.36 | -95.34 | -96.85 | -71.17 | 14.76 | 38.42 |
EBITDA Margin | -16.52% | -8.72% | -24.43% | -22.97% | 2.44% | 7.39% |
D&A For EBITDA | -5.68 | 8.16 | 26.61 | 20.52 | 15.91 | 11.96 |
EBIT | -180.68 | -103.5 | -123.46 | -91.69 | -1.15 | 26.47 |
EBIT Margin | -16.01% | -9.47% | -31.14% | -29.59% | -0.19% | 5.09% |
Effective Tax Rate | - | - | - | - | - | 6.81% |
Revenue as Reported | 1,130 | 1,106 | 396.85 | 310.05 | 605.29 | 521.18 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.